GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study

Loading news article.

GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study | WAPE

GRI Bio Says Phase 2a GRI-0621 IPF Study Showed Placebo-Adjusted FVC Change Of +99 mL At Week 12, +139 mL On Background Antifibrotic Therapy; Says Data Supports Advancement Into Longer-Duration Study

Article summary

Related companies

Comments —